TG Therapeutics, Inc. Announces Third Quarter 2015 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Trump says Canada's Bombardier must build jets in US or lose market access
- European shares subdued as surging crude sharpens focus on ECB rate path
- Wall St slips as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
TG Therapeutics' (TGTX) Q3 Results Solid; Roth Remains Positive into ASH Conference
November 9, 2015 2:20 PM ESTRoth Capital affirmed its Focus Pick rating and $33 price target on TG Therapeutics (NASDAQ: TGTX) following the company's Q3 report and update issued earlier Monday.
Analyst Joseph Pantginis commented, We believe that TG is entering an intriguing time as we look toward more mature data updates at ASH... More
TG Therapeutics (TGTX) Tops Q3 EPS by 6c
November 9, 2015 7:49 AM ESTTG Therapeutics (NASDAQ: TGTX) reported Q3 EPS of ($0.28), $0.06 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $38.1 thousand versus the consensus estimate of $40 thousand.
For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.
... More